PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds

• Status: Terminated
• Trial end date: 2020-08-30
• Target enrollment: 0
• Participant gender: All

Summary

To treat Pakistani patients with non-life threatening symptomatic SARS-CoV-2 infection with an intent to reduce burden on institutional healthcare services by determining efficacy of different chloroquine and hydroxychloroquine dosing regimens in controlling SARS-CoV-2 infection.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Government of Punjab, Specialized Healthcare and Medical Education Department
• Collaborators: Mayo Hospital Lahore; Pakistan Kidney and Liver Institute; Services Hospital, Lahore
• Treatments: Chloroquine; Hydroxychloroquine

Criteria

Inclusion Criteria:

1. Symptomatic patients: defined as fever (temperature greater than 100 degree F), cough, or shortness of breath (respiratory rate >22 per minute).

2. Nasopharyngeal RT-PCR positive SARS-CoV-2

3. Age 20-50 years

4. BMI 18-28 kg/m2

5. Informed consent

Exclusion Criteria:

1. O2 saturation by pulse-oximeter below 93%

2. Co-morbidities: any pre-existing cardiac disease, pulmonary disease, diabetes

3. Arrhythmias and/or history of arrythmia

4. Psoriasis and/or history of psoriasis

5. Neuropathy or myopathy and/or history of these

6. Hypoglycemia and/or history of hypoglycemia

7. Pre-existing hepatic disease

8. Pre-existing renal disease

9. Use of antacids within 1 week

10. Use of antiobiotics within 1 week

11. Pregnancy

12. RT-PCR performed >7 days prior to enrollment